Encephalomyelitis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Encephalomyelitis - Pipeline Review, H1 2019’, provides an overview of the Encephalomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis

- The report reviews pipeline therapeutics for Encephalomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Encephalomyelitis therapeutics and enlists all their major and minor projects

- The report assesses Encephalomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Encephalomyelitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Aurigene Discovery Technologies Ltd

Biovista Inc

Hemispherx Biopharma Inc

ImmuneBiotech AB

Inflazome Ltd

K-Pax Pharmaceuticals Inc

Philogen SpA

Astellas Pharma Inc

Aurigene Discovery Technologies Ltd

Biovista Inc

Hemispherx Biopharma Inc

ImmuneBiotech AB

Inflazome Ltd

K-Pax Pharmaceuticals Inc

Philogen SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalomyelitis – Overview

Encephalomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalomyelitis – Overview

Encephalomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalomyelitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalomyelitis – Companies Involved in Therapeutics Development

Astellas Pharma Inc

Aurigene Discovery Technologies Ltd

Biovista Inc

Hemispherx Biopharma Inc

ImmuneBiotech AB

Inflazome Ltd

K-Pax Pharmaceuticals Inc

Philogen SpA

Encephalomyelitis – Drug Profiles

ASP-4058 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-38 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JM-4 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPAX-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCC-950 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nonathymulin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORNx-KI – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Fatigue Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetravil – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WEHI-345 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalomyelitis – Dormant Projects

Encephalomyelitis – Product Development Milestones

Featured News & Press Releases

Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Encephalomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Encephalomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Encephalomyelitis – Pipeline by Astellas Pharma Inc, H1 2019

Encephalomyelitis – Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Encephalomyelitis – Pipeline by Biovista Inc, H1 2019

Encephalomyelitis – Pipeline by Hemispherx Biopharma Inc, H1 2019

Encephalomyelitis – Pipeline by ImmuneBiotech AB, H1 2019

Encephalomyelitis – Pipeline by Inflazome Ltd, H1 2019

Encephalomyelitis – Pipeline by K-Pax Pharmaceuticals Inc, H1 2019

Encephalomyelitis – Pipeline by Philogen SpA, H1 2019

Encephalomyelitis – Dormant Projects, H1 2019

Encephalomyelitis – Dormant Projects, H1 2019 (Contd..1), H1 2019

List of Figures

List of Figures

Number of Products under Development for Encephalomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Encephalomyelitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports